Telemedicine-Enabled Medication Optimization for Adults with Polypharmacy: A Systematic Review and Implications for Saudi Vision 2030 Healthcare Transformation.
- 1Medical Engagement Department, Health Horizon Medical Co., Jeddah 21323, Saudi Arabia.
Abstract
Background/objectives
Polypharmacy may increase the risk of medication discrepancies, drug-drug interactions, potentially inappropriate prescribing, nonadherence, adverse drug events, and avoidable healthcare use. Telemedicine may improve access to medication review, particularly for older adults, people with multimorbidity, and geographically underserved populations. This review evaluated the effectiveness, safety, acceptability, and implementation requirements of telemedicine-enabled medication optimization and considered implications for Saudi Vision 2030.Methods
This PRISMA 2020 systematic review searched PubMed/MEDLINE, Europe PMC, and ClinicalTrials.gov from inception to 30 June 2026. Eligible studies evaluated telemedicine-supported medication reconciliation, medication therapy management, deprescribing, adherence support, or clinical-pharmacy consultation in adults with polypharmacy or explicitly defined high medication risk. Two reviewers independently screened records and extracted data. Clinical and methodological heterogeneity required narrative synthesis.Results
The search identified 168 records; 52 duplicates were removed, 12 reports underwent full-text assessment, and eight studies were included. Green et al. randomized 69 patient-care-partner dyads to immediate or delayed pharmacist telehealth deprescribing; approximately 80% in each arm completed the intervention, but changes in total medication count and regimen complexity were small and the latter was not clinically meaningful. Cole et al. reported 30-day readmission in 12/76 pharmacist-contacted patients and 3/12 patients who declined or could not be reached (p = 0.529); this nonrandomized comparison does not establish a reduction in readmissions. Process outcomes, including identification of discrepancies, interactions, and potentially inappropriate medicines, were more consistently favorable than clinical outcomes. Certainty was low for detection of medication-related problems and very low or absent for most clinical, utilization, and economic outcomes.Conclusions
Telemedicine-enabled medication optimization appears feasible, but evidence of clinical effectiveness and cost savings remains uncertain. Saudi implementation should begin with monitored pilots emphasizing safety, equity, Arabic-language accessibility, governance, and prospective evaluation.Registration
This completed review was retrospectively registered on the Open Science Framework (OSF).
Related
- Structured medication reviews for adults with multimorbidity and polypharmacy in primary care: a systematic review
- A Narrative Review of Medication Optimisation in Older Adults with Polypharmacy: From Structured Medication Review to AI-Enabled Medication Safety.
- The Effect of Medication Self-Management During Hospitalisation (SelfMED) on Medication Adherence Post-Discharge in Oncology Patients with Polypharmacy: A Prospective, Exploratory, Single-Centre, Non-Randomised Pre-Post Intervention Study with Sequential Control and Intervention Cohorts.
- Structured medication reviews for polypharmacy: evidence and implementation across Europe
- Inverse care law in polypharmacy and medication review among older adults: a population-based study
BibTeX
@article{bawazir2026telemedicineenabled,
title = {{Telemedicine-Enabled Medication Optimization for Adults with Polypharmacy: A Systematic Review and Implications for Saudi Vision 2030 Healthcare Transformation.}},
author = {Bobakr Bawazir and Yaslam Ba Srada and Saad Mohammad Aghi and Mohamed Elsayed and Hisham Yousif and Mohamed Ibrahim and Kareem Eltohamy and Mark Sim},
journal = {Clinics and practice},
year = {2026},
month = oct,
doi = {10.3390/clinpract16100187},
url = {https://europepmc.org/article/MED/42930373},
note = {CC BY},
}
RIS
TY - JOUR
TI - Telemedicine-Enabled Medication Optimization for Adults with Polypharmacy: A Systematic Review and Implications for Saudi Vision 2030 Healthcare Transformation.
AU - Bobakr Bawazir
AU - Yaslam Ba Srada
AU - Saad Mohammad Aghi
AU - Mohamed Elsayed
AU - Hisham Yousif
AU - Mohamed Ibrahim
AU - Kareem Eltohamy
AU - Mark Sim
PY - 2026
DA - 2026/10/09
JO - Clinics and practice
DO - 10.3390/clinpract16100187
UR - https://europepmc.org/article/MED/42930373
AB - Background/objectives Polypharmacy may increase the risk of medication discrepancies, drug-drug interactions, potentially inappropriate prescribing, nonadherence, adverse drug events, and avoidable healthcare use. Telemedicine may improve access to medication review, particularly for older adults, people with multimorbidity, and geographically underserved populations. This review evaluated the effectiveness, safety, acceptability, and implementation requirements of telemedicine-enabled medication optimization and considered implications for Saudi Vision 2030.Methods This PRISMA 2020 systematic review searched PubMed/MEDLINE, Europe PMC, and ClinicalTrials.gov from inception to 30 June 2026. Eligible studies evaluated telemedicine-supported medication reconciliation, medication therapy management, deprescribing, adherence support, or clinical-pharmacy consultation in adults with polypharmacy or explicitly defined high medication risk. Two reviewers independently screened records and extracted data. Clinical and methodological heterogeneity required narrative synthesis.Results The search identified 168 records; 52 duplicates were removed, 12 reports underwent full-text assessment, and eight studies were included. Green et al. randomized 69 patient-care-partner dyads to immediate or delayed pharmacist telehealth deprescribing; approximately 80% in each arm completed the intervention, but changes in total medication count and regimen complexity were small and the latter was not clinically meaningful. Cole et al. reported 30-day readmission in 12/76 pharmacist-contacted patients and 3/12 patients who declined or could not be reached (p = 0.529); this nonrandomized comparison does not establish a reduction in readmissions. Process outcomes, including identification of discrepancies, interactions, and potentially inappropriate medicines, were more consistently favorable than clinical outcomes. Certainty was low for detection of medication-related problems and very low or absent for most clinical, utilization, and economic outcomes.Conclusions Telemedicine-enabled medication optimization appears feasible, but evidence of clinical effectiveness and cost savings remains uncertain. Saudi implementation should begin with monitored pilots emphasizing safety, equity, Arabic-language accessibility, governance, and prospective evaluation.Registration This completed review was retrospectively registered on the Open Science Framework (OSF).
SN - 2039-7275
SN - 2039-7283
ER -